Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check7 days agoChange DetectedVienna study sites are now listed with Completed status and specific postal codes; a Nouvelle-Aquitaine site (Pessac) was removed and a New Aquitaine site (Pessac) was added.SummaryDifference0.4%

- Check14 days agoChange DetectedA new site, Clinica Amo - Rio Vermelho in Salvador, Bahia (ID 231604), was added and marked as Completed on 2026-04-08, updating the ZIP code to 41950-640 and replacing the previous Recruiting entry at 41950-610.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedAdded Gazi Universitesi (Ankara, Türkiye) as site 265425, bringing total locations to 316. Cross Cancer Institute (252065) and Asklepios Fachkliniken München-Gauting (272768) were added, updating the site count from 315 to 316.SummaryDifference0.1%

- Check50 days agoChange DetectedAdded Jeroen Bosch Ziekenhuis as a recruitment site in 's-Hertogenbosch, Netherlands (ID 234087); total locations updated to 315.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a minor update to the site. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.